Zoetis expands companion animal pain management portfolio

17/07/2026

The growing demand for long-term management of chronic diseases in companion animals continues to drive investment and innovation across the animal health industry, with Zoetis expanding its pain management portfolio following the UK approval of Lenivia for canine osteoarthritis. The development reflects the commercial importance of one of the fastest-growing therapeutic segments in companion animal health.

Canine osteoarthritis affects millions of dogs worldwide and is one of the leading causes of chronic pain, reduced mobility and declining quality of life in ageing pets. As companion animals live longer and owners increasingly seek advanced treatment options, demand for long-term pain management continues to grow.

The UK approval of Lenivia adds a new biologic therapy to the veterinary toolkit, providing veterinarians with an additional option for managing chronic osteoarthritis pain. According to Zoetis, the monoclonal antibody treatment is specifically designed to target pain associated with canine osteoarthritis while supporting improved mobility and daily function.

The approval reflects a broader shift across the companion animal sector towards innovative biologic therapies for chronic diseases. As veterinary medicine continues to evolve beyond traditional pharmaceuticals, biologics are becoming an increasingly important area of investment for animal health companies.

For veterinary practices, expanding treatment options may strengthen long-term case management while encouraging ongoing client engagement through regular monitoring and follow-up care. At the same time, growing demand for advanced therapies is creating new opportunities across the companion animal health market.

With chronic diseases becoming more prevalent in ageing pet populations, pain management is expected to remain a strategic growth area for the industry. Continued investment in innovative therapies is likely to play an important role in improving patient outcomes while supporting the long-term expansion of the companion animal sector.

For more information: Zoetis